ClinicalTrials.gg
Active, not recruitingNCT06238479EXCEEDUpdated May 22, 2026

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of LY4101174 in Metastatic Solid Tumor, Recurrent Solid Tumor and Advanced Solid Tumor, sponsored by Eli Lilly and Company. Active, not recruiting at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
490
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.

Planned enrollment
8th of 66
490 · median 77
Started
2024
with 3 others
Phase 1
43 of 72
3 open now
Primary completion
2027-03
later than 5 of 15 live
Registered
63rd of 72
by date

Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 8th largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 5 of the 15 other live ones, and was the 63rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neoplasm Metastasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.

Read the detailed description

This is a Phase 1a/1b multicenter, open-label study in participants with select advanced or metastatic solid tumors. This study is comprised of two phases: Dose Escalation and Dose Optimization (1a), and Dose expansion (1b). Phase 1a will assess the safety, tolerability, and pharmacokinetics of LY4101174 to determine the recommended phase 2 dose (RP2D)/optimal dose. Phase 1b will evaluate efficacy and safety of LY4101174 at the RP2D/optimal dose in 7 expansion cohorts based on tumor type and/or treatment history. At the completion of the trial, participants will have the option to continue receiving study drug at the discretion of the study doctor.

03

Conditions studied

  • Metastatic Solid Tumor
  • Recurrent Solid Tumor
  • Advanced Solid Tumor
  • Urinary Bladder Neoplasm
  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Prostate Cancer
  • Renal Pelvis Cancer
  • Bladder Cancer

Keywords

  • Bladder Cancer
  • Bladder Neoplasm
  • Bladder Urothelial Carcinoma
  • Urinary Bladder Cancer
  • Urinary Tract Cancer
  • Urothelial Neoplasms
  • Renal Pelvis Cancer
  • Ureter Cancer
  • Nectin-4
  • Antibody Drug Conjugate (ADC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following solid tumor cancers:

    • Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer
    • Cohort A2/B1/B2: urothelial carcinoma
    • Cohort C1: triple negative breast cancer
    • Cohort C2: non-small cell lung cancer
    • Cohort C3: ovarian or fallopian tube cancer
    • Cohort C4: cervical cancer
    • Cohort C5: head and neck squamous cell carcinoma
  • Prior Systemic Therapy Criteria:

    • Cohort A1/C1-5: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies
    • Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or setting. There is no restriction on number of prior therapies.
  • Prior enfortumab vedotin specific requirements:

    • Cohorts A1/A2/C1-5: prior treatment with enfortumab vedotin is allowed, but not required
    • Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting
    • Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.
  • Measurability of disease

    • Cohort A1: measurable or non- as defined by v1.1 (RECIST 1.1)
    • Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1
  • Have an (ECOG) performance status of 0 or 1
  • Have adequate sample available or undergo a screening biopsy if allowed per country specific regulations

Exclusion criteria

Exclusion Criteria:

  • Individual with known or suspected uncontrolled
  • Individual with uncontrolled hypercalcemia
  • Individual with uncontrolled diabetes
  • Individual with evidence of corneal keratopathy or history of corneal transplant
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Current of history of intestinal obstruction in the previous 3 months
  • Recent thromboembolic event and/or bleeding
  • Prolongation of corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms
  • History of pneumonitis/interstitial lung disease
  • History of Grade ≥3 skin toxicity when receiving enfortumab vedotin
  • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
  • Individual with active uncontrolled infection
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    LY4101174 (Dose-escalation, Cohort A1)

    Escalating doses of LY4101174 administered intravenously (IV).

    Drug: LY4101174

  • Experimental
    LY4101174 (Dose-optimization, Cohort A2)

    Comparing 2 or more doses (evaluated during dose escalation) of LY4101174 administered IV.

    Drug: LY4101174

  • Experimental
    LY4101174 (Dose-expansion, Cohort B1, B2, C1-C5)

    LY4101174 administered IV.

    Drug: LY4101174

Interventions

  • DrugLY4101174

    Intravenous

06

What researchers measure

Primary outcomes

  1. Phase 1a: To determine the recommended dose of LY4101174

    Number of participants with dose-limiting toxicities (DLTs)

    Time frame: First 2 Cycles (28 days)

  2. Phase 1a: To determine the recommended phase 2 dose (RP2D) or optimal dose of LY4101174

    Number of participants with DLTs

    Time frame: First 2 Cycles (28 days)

  3. Phase 1b: To assess the antitumor activity of LY4101174 Monotherapy: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 48 Months or 4 Years

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) properties of LY4101174: Minimum Plasma Concentration (Cmin)

    PK: Cmin of LY4101174

    Time frame: First 4 cycles (56 days)

  2. To characterize the PK properties of LY4101174: Area under the concentration versus time curve (AUC)

    PK: AUC of LY4101174

    Time frame: First 4 cycles (56 days)

  3. To evaluate the preliminary antitumor activity of LY4101174: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 48 Months or 4 Years

  4. To evaluate the preliminary antitumor activity of LY4101174: Duration of response (DOR)

    DOR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  5. To evaluate the preliminary antitumor activity of LY4101174: Time to response (TTR)

    TTR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  6. To evaluate the preliminary antitumor activity of LY4101174: Progression free survival (PFS)

    PFS per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  7. To evaluate the preliminary antitumor activity of LY4101174: Disease control rate (DCR)

    DCR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  8. To evaluate the preliminary antitumor activity of LY4101174: Overall survival (OS)

    OS per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

07

Study locations

28 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 2, 2024
StartActual
Mar 5, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238479
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Mar 5, 2024
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 22, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion